Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
26 Feb 2020 Annual Corporate Governance Report ROVI releases the 2019 Annual Corporate Governance Report Download
26 Feb 2020 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors  Download

Pages

Date Title Description PDF
31 Jan 2020 R&D: new licenses, patents and registered trademarks The Company informs about the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union Download
08 Jan 2020 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2019 Download
20 Dec 2019 Composition of the board of directors The Company informs about the composition of its Board of Directors and its Audit and Appointments and Remuneration Committees. Download
24 Nov 2019 Strategic plans, profit forecasts and presentations The Company releases the presentation related to its strategy update because of the 2019 Investor Day. Download
07 Nov 2019 Information on P&L ROVI releases the press release related to the first nine months 2019 financial results Download

Pages